Related knowledge about ceritinib/ceritinib capsules

Ceritinib is an oral targeted drug, marketed in capsule form, with a common strength of 150 mg. The drug is a second-generation ALK inhibitor specifically used to treat patients with ALK-positive non-small cell lung cancer (NSCLC), especially those who are resistant or intolerant to crizotinib. Since the proportion of ALK-positive lung cancer in lung cancer is low, ceritinib is highly targeted and can effectively inhibit tumor growth driven by ALK mutations.

The way you take ceritinib has a great impact on its efficacy and side effects. The initially recommended dose was 750 mg (once a day, on an empty stomach). However, due to strong gastrointestinal adverse reactions, subsequent studies found that changing to 450 mg with meals can significantly reduce the incidence of nausea, vomiting and diarrhea while maintaining drug efficacy. Therefore, the current mainstream way of taking it is to take 450mg with food every day to improve the patient's tolerance.

Patients need to pay attention to drug interactions while taking ceritinib. This drug is mainly metabolized by CYP3A4 enzyme, so combination with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin, carbamazepine) should be avoided to prevent affecting drug concentration. In addition, ceritinib may cause QT interval prolongation, so caution should be used when combined with other drugs that may affect the electrical activity of the heart (such as certain antibiotics and antipsychotic drugs).

In terms of storage, ceritinib capsules should be placed at room temperature (15-30℃), away from moisture and direct sunlight to ensure drug stability. Patients should strictly follow the doctor's instructions and conduct regular liver function, blood sugar and heart monitoring to ensure the safety of treatment.

Generally speaking, ceritinib is a second-generation ALK inhibitor. It still plays an important role in crizotinib-resistant patients, and is especially effective against specific drug-resistant mutations and brain metastases.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib